MGT Comments on American Cancer Society's Decision to Endorse CT Co... (Weexpect the Company and its CAD softwar...)

MGT Comments on American Cancer Society's Decision to Endorse CT Colonography

Date:3/7/2008

We expect the Company and its CAD software to be an important beneficiary of wider use of CTC screening."

Colorectal cancer is the second leading cause of cancer death in the US. However when detected early the survival rate is high. Those most at risk, aged 50 or older, are recommended to be screened regularly. However as the conventional optical colonoscopy procedure, involving the insertion of a flexible metal tube into the colon is very uncomfortable less than half actually undergo colonoscopy. CTC scanning, which Medicsight has honed with its superior ColonCAD(TM) software, offers patients with an alternative routine screening method for early detection, which is non-invasive and more comfortable.

The guidelines, titled Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008, were jointly released by the ACS, the U.S. Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Under these guidelines the accepted testing options for the early detection of colorectal cancer include the following:

-- CTC (recommended every five years);

-- colonoscopy (recommended every 10 years);

-- flexible sigmoidoscopy (recommended every five years);

-- double contrast barium enema (recommended every five years);

-- annual guaiac fecal occult blood testing (gFOBT); and

-- annual faecal immunochemical test (FIT).

The ACS decision to add CTC to the guidelines is based on the outcomes of recent large clinical studies confirming that CTC is comparable to optical colonoscopy for detecting cancer and polyps of significant size when state-of- the-art techniques are applied. Positive clinical studies published in recent months include the National CT Colonography Trial (ACRIN 6664), research from the University of Wisconsin Medical School in Madison published in the New England Journal of Medicine, the IMPACT trial from Italy, and the Munich Colorectal
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
2. QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million
3. The Branded Pharmaceutical Association Comments on Hydrocodone
4. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
5. Pelosi Statement on Stark Comments
6. American College of Surgeons Comments on JAMA Article on Surgeon Shortage
7. URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation Programs
8. Boston Scientific Comments on New England Journal of Medicine Article
9. American Legacy Foundation Comments on New York State Department of Health Petition to the FDA to Expand Consumer Access to Over the Counter Nicotine Medications
10. URAC Invites Health Management Industry, Public for Comments on Changes to Its Core Accreditation Standards
11. Many Older Americans Have Active Sex Lives

Post Your Comments:

MGT Comments on American Cancer Society's Decision to Endorse CT Co...(Weexpect the Company and its CAD softwar...),Health